What is the role of bevacizumab in the treatment of choroidal neovascularization (CNV)?

Updated: Jul 27, 2020
  • Author: Lihteh Wu, MD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print

Bevacizumab is a humanized, recombinant monoclonal immunoglobulin G (IgG) antibody that binds and inhibits all VEGF isoforms and is currently approved for systemic use in metastatic colorectal cancer and non–small cell lung cancer.

Off-label use of intravitreal bevacizumab for CNV secondary to ARMD was first reported in 2005. Most of the reports of bevacizumab are uncontrolled, open-label case series that have suggested functional and anatomical efficacy, short-term safety, and low cost.

Results from several studies suggest that bevacizumab may be useful in the treatment of CNV secondary to multiple etiologies including myopia, [39] angioid streaks, [40] inflammatory conditions, [41, 42] and ARMD. [43, 44]

A retrospective study reported findings in 180 patients with choroidal neovascularization secondary to age-related macular degeneration who were injected with either 1.5 mg or 2.5 mg and were followed for a minimum of 24 months. [45] An average of 5 injections using a PRN protocol demonstrated improvement or stability in vision. No statistically significant differences between doses were noted.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!